Mergers

Qiagen Takeover Timeline: Every Step to a Mid-2027 Close

EQT's €46.50 Qiagen offer still needs BaFin approval before NYSE holders can tender, and closing is expected in mid-2027. Here is each step from the offer document to delisting, with known dates and the ones not yet announced.

Qiagen Takeover Timeline: Every Step to a Mid-2027 Close

The Qiagen takeover has not reached the tender stage yet. As of November 11, 2026, Germany's BaFin had not approved EQT's offer document, so no acceptance period or US tender offer has started. Closing is expected in mid-2027. From here the path runs through BaFin approval, a 10-week acceptance period with a parallel US offer, an extraordinary general meeting, the 50%-plus-one and 80% tests, and merger and foreign-investment clearances. After that come closing, the back-end Post-Closing Measures and the delisting of $QGEN from the NYSE. Below is each step, what triggers it, and which dates are fixed and which are not.

Qiagen takeover timeline: known dates and open ones

Only dates that are documented appear below. Windows set by the deal agreement are labeled as such, and everything else is marked "not yet announced".

DateStepStatus
Jul 8, 2026Unaffected XETRA close of €33.15, the base for the premiumFixed
Oct 21, 2026Business Combination Agreement signed; offer of €46.50 cash announcedDone
Oct 22 and 28, 2026Pre-commencement filings with the SEC (SC TO-C, SC 14D-9C)Done
Nov 6, 2026Q3 report filed on Form 6-K; still no Schedule TODone
Nov 18 to Dec 16, 2026Offer document due at BaFin: four weeks after the announcement, or up to eight weeks if BaFin grants an extensionWindow under the agreement; filing date not yet announced
Not yet announcedBaFin clearance, publication of the offer document, start of the acceptance period, Schedule TO filedNot yet announced
Not yet announcedEGM, held during the initial acceptance periodNot yet announced
Not yet announcedEnd of the 10-week acceptance period, then a two-week additional acceptance periodNot yet announced
Aug 21, 202710 months after the announcement: possible interim dividend of up to $0.47 if regulatory approvals are still pendingConditional
Mid-2027Expected closingCompany expectation
Jan 21, 2028Long stop date, 15 months after signingContract deadline

The August 21, 2027 and January 21, 2028 dates are arithmetic from October 21, 2026, using the 10-month clause in the joint press release and the 15-month long stop in the Business Combination Agreement. On the price itself, the €46.50 offer was worth about $52.18 against a $50.51 $QGEN close on November 10, 2026. Our main page on the EQT offer covers that spread.

Step 1: BaFin approval and the offer document

Qiagen is a Dutch company listed in Frankfurt, so the offer runs under the German Securities Acquisition and Takeover Act, and BaFin must approve the offer document before it can be published. The agreement lets the bidder ask BaFin to extend the submission window from four to as many as eight weeks. It also lets the bidder consult BaFin about stretching BaFin's review period from 10 to 15 working days.

When BaFin clears the document, the bidder will post it in German, with a non-binding English translation, at eqt-offer.com. On November 11, 2026, that site still said the document will be published only after BaFin permits it. Qiagen's boards will then publish their formal recommendation in a reasoned position statement, and Qiagen will file a Schedule 14D-9 with the SEC.

Step 2: the acceptance period and the US tender offer

On the day the offer document comes out, the bidder will also launch the offer in the United States and file a Schedule TO with the SEC. For NYSE holders, that filing is the trigger to watch, because it is the document that sets out how to tender.

  • Initial acceptance period: 10 weeks from commencement, subject to statutory extensions, and in no case shorter than 20 US business days.
  • Additional acceptance period: two more weeks after the first results are published, if every condition except the regulatory ones has been met or waived.
  • Payment: settlement follows the later of the additional-period results and satisfaction of all conditions, and the parties will seek SEC approval for a payment window of no more than 10 business days. Holders whose shares sit with a US custodian will get a process for receiving US dollars.

Step 3: the EGM and the 50%-plus-one and 80% tests

Two separate thresholds apply. They are easy to mix up.

  1. Acceptance threshold: by the end of the acceptance period, tendered shares plus shares the bidder already holds must be at least 50% of the outstanding capital plus one share.
  2. EGM approval: the EGM, held during the initial acceptance period, must adopt the demerger, share-sale and governance resolutions. Under Qiagen's articles and Dutch law that takes a simple majority of votes cast, or two-thirds if less than half of the issued capital is represented.

The 80% figure sits on top of these. If at least 80% of votes cast approve the Post-Closing Measures, the boards will take the Implementation Decision. If support is lower, the boards may still go ahead if their fiduciary duties allow and "a substantial majority" of shareholders support the deal. In judging that, they may discount votes from holders who bought after the announcement to frustrate the deal or to pursue event-driven hedge fund strategies. The Implementation Decision is itself an offer condition and must be in place before the acceptance period ends.

Step 4: regulatory clearances

Merger-control clearances and foreign-investment approvals must arrive before the long stop date. The conditions name CFIUS in the United States specifically. If every other condition is met, regulators set the pace, which is why the company guides to mid-2027 even though the tender itself takes about three months. If the deal dies on these approvals, the buyer owes Qiagen a €300 million reverse termination fee.

Step 5: closing, Post-Closing Measures and delisting

After settlement, EQT aims to own 100% of the business. If the bidder reaches 95% of the outstanding capital, it can use a Dutch statutory squeeze-out, but the agreement says it is never obliged to. The main route is the Post-Closing Measures. Qiagen moves substantially all of its business into a new subsidiary through a demerger, sells that subsidiary to the buyer, and then liquidates. Remaining holders get an advance liquidation distribution equal to the offer price, without interest.

Applicable withholding taxes may be deducted from that distribution, and the agreement refers specifically to Dutch dividend withholding tax. The companies warn this "may result in a lower net amount" than tendering. This is general information, not tax or legal advice. In connection with these steps, the NYSE and Frankfurt listings will be terminated.

Step 6: the 10-month interim-dividend clause

If closing has not happened within 10 months of October 21, 2026 because regulatory approvals are still pending, Qiagen may choose to pay an interim dividend of up to $0.47 a share. It would not be deducted from the €46.50 price. The clause says "may", so a delay does not guarantee the payment.

The 2020 Thermo Fisher bid failed at the tender step, not at the regulators. Our review of that bid explains how, and our comparison of the 2020 and 2026 bids sets the two side by side. For more coverage, see the Analysis section or the homepage.

Bull/Bear Verdict

Bull Case: Every step is mapped in a signed agreement: a 10-week tender with a two-week extra window, a 50%-plus-one bar, boards able to proceed below 80%, a €300 million reverse fee if regulators block the deal, and a possible $0.47 dividend if approvals drag.

Bear Case: The schedule has no fixed dates yet. Offer document timing, the EGM vote and the regulatory reviews, including CFIUS, can each slip toward the January 21, 2028 long stop, and holders who never tender face possible withholding tax at the back-end.

FAQ

Can I tender my $QGEN shares in the Qiagen takeover yet?

Not as of November 11, 2026. The acceptance period starts only when BaFin approves the offer document and it is published. The US offer and the Schedule TO filing begin the same day.

How long is the Qiagen acceptance period?

Ten weeks from the start, subject to statutory extensions, and at least 20 US business days. If all non-regulatory conditions are met, a two-week additional acceptance period follows.

When is the Qiagen EGM?

It has not been scheduled. The agreement places it during the initial acceptance period, which has not started.

What if regulators take longer than expected?

If approvals are still pending 10 months after October 21, 2026, Qiagen may pay an interim dividend of up to $0.47 a share, not deducted from the offer price. If competition or investment-screening clearances are still missing at the January 21, 2028 long stop date, either side can terminate the agreement.

Share X LinkedIn Email
Disclaimer: The information provided is for informational purposes only and is not intended as financial, legal, or tax advice. Trading around earnings involves significant risk and increased volatility. Past performance is not indicative of future results. No strategy can guarantee profits or protect against loss. Consult a professional advisor before acting on any information provided.

More in Mergers · Full archive